Opexa licenses MS T-cell therapy to Merck Serono for up to $225M

02/6/2013 | Genetic Engineering & Biotechnology News

Merck Serono has signed a deal with Opexa Therapeutics for the option to acquire exclusive development and marketing rights to Opexa's Tcelna, or imilecleucel-T, an experimental personalized T-cell treatment for multiple sclerosis, in all countries except Japan. Opexa received $5 million upfront, and would get an additional $25 million or $15 million if Merck exercises the option. Opexa is also eligible to receive as much as $195 million in milestone fees plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations